Mergers, acquisitions, take-privates, and large corporate transactions. We surface the deal terms, regulatory considerations, and competitive implications across every announcement.
GSK will gain two lung cancer candidates already under FDA review for 2026 approval, making the pipeline acceleration the primary strategic rationale...
Analysis
GSK's investment thesis now hinges on two FDA decisions expected in 2026; a rejection or complete response letter on either submission would impair the deal's near-term return and likely reprice GSK equity. The $10.6bn outlay represents one of GSK's largest deals in over a decade, concentrating execution risk in a binary regulatory calendar. Investors should watch FDA PDUFA dates for Nuvalent's two lead assets as the primary near-term valuation event.
Google has agreed to rent computing capacity from SpaceX at $920 million per month, generating a total contract value of approximately $30 billion...
Alphabet sourcing external compute at $920 million per month directly contradicts the narrative embedded in its $85bn equity raise, which earmarked $40bn for internal AI infrastructure build-out. The two moves in combination suggest Alphabet's own data centre capacity is insufficient to meet demand it described as 'exceeding available supply', validating the supply constraint thesis. This is modestly positive for third-party AI infrastructure operators and server OEMs, and raises the question of whether Google's internal capex guidance is understated.
UMG's board rejection leaves Pershing Square without a path to a US relisting of the world's largest music company, dealing a significant setback to...
UMG's pledge of 'enhanced financial disclosures' creates a near-term re-rating catalyst for the stock independent of the takeover outcome. Bolloré's 18% stake and the board's own acknowledgment of valuation pressure suggest consensus NAV estimates are materially below intrinsic value. Improved disclosure on streaming royalty economics and label-level profitability could close part of that gap without any deal premium, benefiting existing UMG shareholders including Pershing Square.
OKX Ventures and Korea Investment & Securities together acquire a 19.6% stake in South Korean crypto exchange Coinone, marking one of the larger...
OKX's simultaneous involvement in UK Premier League crypto sponsorship scrutiny (FCA warning lists BingX and OKX as lacking FCA authorisation for Chelsea and Manchester City deals) and this South Korean institutional equity stake creates a bifurcated regulatory posture: OKX is building licensed institutional infrastructure in Asia while facing enforcement exposure in the UK. If the FCA action escalates, it could complicate OKX Ventures' ability to deploy capital into further regulated-market partnerships.
Berkshire Hathaway's purchase of Taylor Morrison removes the largest publicly traded pure-play homebuilder from U.S. Equity markets and concentrates...
Berkshire's simultaneous $10bn anchor investment in Alphabet's $85bn equity raise and $8.5bn all-cash homebuilder acquisition signals that Greg Abel is deploying capital at a pace and into asset classes that diverge materially from Buffett's late-career posture of cash accumulation. Two large committed outflows within weeks of Abel's tenure beginning will focus investor attention on whether Berkshire's cash reserve is being structurally redeployed, with implications for BRK.B's conglomerate discount.
MGM Resorts shares jumped 14% after People Inc. Launched a take-private offer, confirming Diller's April assertion that the stock was 'wildly...
MGM's 14% jump on the bid creates a spread-trading setup contingent on special committee formation and competing bids. People Inc.'s existing 26% stake raises the acquisition threshold for any rival bidder and limits the realistic pool of counteroffers, capping the upside scenario for merger arbitrage. The $48.30 offer already reflects a meaningful premium; without a competing bid, arb spreads will price the deal at a discount to the offer given deal execution risk and the absence of board endorsement.